Developing a system for early detection of Alzheimer's disease
The Development of Early-stage Alzheimer's Disease Multimodal Fusion Warning System and Non-invasive Neurostimulation Techniques.
This study is testing a new digital tool and treatment to see if it can help find Alzheimer's disease early in people and improve their cognitive health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 55 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT05978830 on ClinicalTrials.gov |
What this trial studies
This study aims to create and validate a digital recognition device and a multimodal warning model for early detection of Alzheimer's disease. Participants will undergo clinical assessments and have their cognitive functions evaluated through various scales and advanced imaging techniques, including EEG and MRI. The study also involves a precision transcranial ultrasound stimulation intervention, where participants are randomly assigned to receive either true or false stimulation over a period of weeks, followed by assessments to evaluate the therapeutic effects.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 55 to 80 diagnosed with mild cognitive impairment or Alzheimer's disease.
Not a fit: Patients with other forms of dementia or significant mental health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and intervention for Alzheimer's disease, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using multimodal approaches for early detection of Alzheimer's, but this specific combination of techniques is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with MCI / AD 2. Between the ages of 55 and 80 3. No history of mental illness such as schizophrenia, severe anxiety and depression Exclusion Criteria: 1. Consistent with Parkinson's disease, frontotemporal dementia, dementia with lewy bodies Or Huntington's disease diagnostic criteria 2. Dementia due to other causes (e.g. cerebrovascular disease, central nervous system trauma, tumors, infections, Metabolic diseases, normal stress hydrocephalus, folic acid or vitamin B12 deficiency, hypothyroidism, etc.) 3. Have aphasia,Disorders that affect cognitive assessment, such as disorders of consciousness 4. Have a history of epilepsy or take antiepileptic drugs
Where this trial is running
Hangzhou, Zhejiang
- Yi Ling — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Yi Ling, Dr
- Email: 12118458@zju.edu.cn
- Phone: 15168236137
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.